Adcock Ingram, which counts Panado painkillers and the cold and flu product Corenza C among its brands, plans to bulk up its range of consumer goods products to reduce its dependence on price-regulated medications as it battles the fallout from Covid-19

Acquisitions in the consumer goods space helped the drugmaker grow its turnover in the six months to end-December 2020, though profits fell. CEO Andy Hall said Adcock still has some gaps to fill in terms of personal care and baby products...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.